Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unveiling Post-COVID-19 syndrome: incidence, biomarkers, and clinical phenotypes in a Thai population.
Sangkaew S, Tumviriyakul H, Cheranakhorn C, Songumpai N, Pinpathomrat N, Seeyankem B, Yasharad K, Loomcharoen P, Pakdee W, Changawej C, Dumrongkullachart D, Limheng A, Dorigatti I. Sangkaew S, et al. Among authors: pinpathomrat n. BMC Infect Dis. 2024 Oct 10;24(1):1132. doi: 10.1186/s12879-024-10055-2. BMC Infect Dis. 2024. PMID: 39385068 Free PMC article.
Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study.
Sripongpun P, Pinpathomrat N, Sophonmanee R, Ongarj J, Seepathomnarong P, Seeyankem B, Chamroonkul N, Piratvisuth T, Kaewdech A; Cirrhosis-COVID-19 Vaccine Study Group. Sripongpun P, et al. Among authors: pinpathomrat n. Vaccines (Basel). 2023 Sep 4;11(9):1455. doi: 10.3390/vaccines11091455. Vaccines (Basel). 2023. PMID: 37766131 Free PMC article.
Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report.
Intapiboon P, Pinpathomrat N, Juthong S, Uea-Areewongsa P, Ongarj J, Siripaitoon B. Intapiboon P, et al. Among authors: pinpathomrat n. Vaccines (Basel). 2023 Feb 24;11(3):537. doi: 10.3390/vaccines11030537. Vaccines (Basel). 2023. PMID: 36992120 Free PMC article.
Characteristics, Outcomes, and Factors Affecting Mortality in Hospitalized Patients with CAP Due to Different Variants of SARS-CoV-2 and Non-COVID-19 CAP.
Tongsengkee N, Surasombatpattana S, Tanomkiat W, Siripaitoon P, Kositpantawong N, Kanchanasuwan S, Navasakulpong A, Pinpathomrat N, Dechaphunkul A, Phongphithakchai A, Hortiwakul T, Charoenmak B, Chusri S. Tongsengkee N, et al. Among authors: pinpathomrat n. J Clin Med. 2023 Feb 9;12(4):1388. doi: 10.3390/jcm12041388. J Clin Med. 2023. PMID: 36835923 Free PMC article.
Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.
Niyomnaitham S, Jongkaewwattana A, Meesing A, Pinpathomrat N, Nanthapisal S, Hirankarn N, Siwamogsatham S, Kirdlarp S, Chaiwarith R, Lawpoolsri S, Phanthanawiboon S, Thitithanyanont A, Hansasuta P, Chaiyaroj S, Pitisuttithum P. Niyomnaitham S, et al. Among authors: pinpathomrat n. Int J Infect Dis. 2023 Apr;129:19-31. doi: 10.1016/j.ijid.2023.01.022. Epub 2023 Jan 20. Int J Infect Dis. 2023. PMID: 36682680 Free PMC article. Clinical Trial.
Humoral SARS-CoV-2 immunogenicity wanes 3 months after heterologous inactivated vaccine followed by ChAdOx1 nCoV-19 in autoimmune rheumatic diseases.
Uea-Areewongsa P, Pinpathomrat N, Ongarj J, Sophonmanee R, Seepathomnarong P, Seeyankem B, Surasombatpattana S, Intapiboon P. Uea-Areewongsa P, et al. Among authors: pinpathomrat n. Asian Pac J Allergy Immunol. 2023 Jan 3. doi: 10.12932/AP-280722-1420. Online ahead of print. Asian Pac J Allergy Immunol. 2023. PMID: 36592166 Free article.
23 results